Tivic Health receives two INDs for Entolimod from Statera for ARS and advanced cancers

Valion Bio, Inc.

Completed transfer of two INDs from Statera Biopharma for lead candidate Entolimod.
INDs cover acute radiation syndrome (ARS-H and ARS-GI sub-syndromes) and advanced cancers.
Enables formal FDA engagement on regulatory pathway for ARS; near-term focus on ARS as first indication.
Also enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-treatment conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.